arrow
J

Jamie Saunders

national institutes of health (nih) - usa
H指数:19
被引数:3,821

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

N6LS的安全性与药代动力学研究:一种广谱中和性抗HIV单克隆抗体——一项在健康成人中进行的1期、开放标签、剂量递增研究

2025-05-200
PRE
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
2024-09-172
OAAI
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
2023-12-0111
PRE
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
2023-05-100
OAAI
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
2022-04-227
OAAI
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center
2021-07-010
OAAI
Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021
2021-07-011
OAAI
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
LEUKEMIA
IF13.4
2021-05-2241
OAAI
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
2019-10-0170
OAAI
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
LANCET
IF88.5
2018-02-01237
OAAI
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection
2017-02-21195
OAAI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination (vol 22, pg 614, 2016)
2016-06-071
PREAI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
2016-05-09288
PREAI
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
LANCET
IF88.5
2014-12-01213
PREAI